[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"allergic-respiratory-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:allergic-respiratory-disease":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100554468",false,"NCT06499480","Italian Registry of Allergen ImmunoTherapy","Italian Registry of Patients With Allergic Disease and Treated With Allergen ImmunoTherapy","RIAIT","Inclusion Criteria:\n\n* Age ≥ 1 year\n* Confirmed diagnosis of allergic rhinoconjunctivitis and\u002For allergic asthma according to EAACI 2019 guidelines.\n* Having been followed by the recruiting center for at least one month: this is considered necessary to establish that the patients are truly affected by allergic respiratory disease and are eligible for allergen-specific immunotherapy; in this period, screening tests are carried out to exclude and\u002For confirm concomitant diseases (comorbidities). In fact, according to the aforementioned EAACI guidelines, a patient can be defined as truly eligible for allergen-specific immunotherapy only after a preliminary phase in which the patient is treated with symptomatic therapy; this observation period allows a correct evaluation of the real adherence and response to therapy, as well as the identification and appropriate treatment of any comorbidity and the possible elimination of aggravating factors.\n* Having received the prescription of any of the available AIT products in Italy, irrespectively of the selected allergens and the administration route and schedule.\n\nExclusion Criteria:\n\nThere will no be exclusion criteria, in order to allow a real-life vision of the characteristics of these patients eligible for or treated with allergen-specific immunotherapy.","ALL","1 Year",{"count":19,"type":20},5000,"ESTIMATED","10 Years","OBSERVATIONAL","RIAIT (Italian Registry of Allergy Immunotherapy) is a multicenter observational study that aims to prospectively collect the most extensive data available on Italian patients using AIT for respiratory allergies (rhinoconjunctivitis and\u002For asthma) in a real-life context, through a network of allergy centers with specific interest and expertise in the management of allergic respiratory patients.",[25],"Allergic Respiratory Disease","RECRUITING","2025-03-03",{"date":29,"type":30},"2025-03-06","ACTUAL",{"date":32,"type":30},"2024-05-01",{"date":34,"type":20},"2035-12-31",{"name":36,"class":37},"Società Italiana di Allergologia, Asma e Immunologia Clinica","OTHER",2,""]